A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-15

Study Completion Date

2022-09-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study CPX351-103 is an open-label, multicenter, phase 1b, safety and PK study to determine the MTD of the combination of CPX 351 and venetoclax when administered to subjects with newly diagnosed AML who are unfit for intensive chemotherapy (ICT) and to determine the recommended phase 2 dose (RP2D) for the Expansion Phase. This study will comprise 2 phases: a Dose Exploration Phase (Part 1) and an Expansion Phase (Part 2), in which all subjects will receive a combination of CPX-351 and venetoclax.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

NCT03629171

Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia

RECRUITING PHASE2

Trial of CPX-351 in Newly Diagnosed Elderly AML Patients

NCT00788892

Acute Myeloid Leukemia

COMPLETED PHASE2

Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia

NCT03335267

Leukemia, Myeloid, Acute

COMPLETED PHASE2

Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)

NCT00822094

Acute Myeloid Leukemia

COMPLETED PHASE2

Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML

NCT03709758

Acute Myeloid Leukemia

ACTIVE_NOT_RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myeloid Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CPX-351 and Venetoclax

CPX-351 and Venetoclax will be administered over 28 day cycles

Group Type EXPERIMENTAL

CPX-351

Intervention Type DRUG

CPX-351 will be administered on Days 1 and 3 of each cycle

Venetoclax

Intervention Type DRUG

Venetoclax will be adminstered on Days 2 to 21 of each cycle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CPX-351

CPX-351 will be administered on Days 1 and 3 of each cycle

Intervention Type DRUG

Venetoclax

Venetoclax will be adminstered on Days 2 to 21 of each cycle

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vyxeos Venclexta

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Subject must have newly diagnosed AML with histological confirmation by World Health Organization (WHO) criteria.

Definition of subjects who are unfit for ICT:

• Each subject must meet the following criteria characterizing him / her as unfit to receive ICT prior to the first day of therapy to be enrolled in the study:

* ≥ 75 years of age OR
* ≥ 18 to 74 years of age and fulfilling at least 1 criteria associated with lack of fitness for ICT as follows:

* Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 to 3;
* Cardiac history of Congestive Heart Failure (CHF) requiring treatment or left ventricular ejection fraction (LVEF) ≤ 50%.
* Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) ≤ 65% or Forced Expiratory Volume in 1 second (FEV1) ≤ 65%;
* Creatinine clearance (CrCl) ≥ 30 mL/min to \< 45 mL/min calculated by the Cockcroft-Gault formula;
* Moderate hepatic impairment with total bilirubin \> 1.5 to ≤ 3.0 × Upper Limit of Normal (ULN);
* Other comorbidity that the physician judges to be incompatible with conventional intensive chemotherapy which must be reviewed and approved by the study medical monitor before study enrollment.

In addition, all subjects must meet the following criteria:

* If the subject is ≥ 75 years of age, then ECOG Performance Status must be 0-2.
* Subject must have adequate renal function as demonstrated by a CrCl ≥ 30 mL/min (calculated by the Cockcroft Gault formula or measured by 24-hour urine collection).
* Subject must have adequate liver function as demonstrated by:

* Aspartate aminotransferase (AST) ≤ 3.0 × ULN\*
* Alanine aminotransferase (ALT) ≤ 3.0 × ULN\*
* Bilirubin ≤ 1.5 × ULN (subjects who are \< 75 years of age may have bilirubin of ≤ 3.0 × ULN)\* \*Unless considered to be due to leukemic organ involvement.
* Female subjects must be either postmenopausal defined as:

* Age \> 55 years with no menses for ≥ 2 years without an alternative medical cause.
* OR
* Age ≤ 55 years with no menses for ≥ 12 months without an alternative medical cause AND a follicle-stimulating hormone level \> 40 IU/L;
* OR
* Permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy); OR
* A woman of childbearing potential practicing at least 1 protocol specified method of birth control starting at Study Day 1 through at least 6 months after the last dose of study treatment.
* A woman of childbearing potential must have negative results for pregnancy test performed:

* At Pretreatment with a serum sample obtained within 28 days prior to the first study treatment administration, and
* Prior to dosing with urine sample obtained on Cycle 1 Day 1, if it has been \> 7 days since obtaining the serum pregnancy test results.
* Subjects with borderline pregnancy tests at Pretreatment must have a serum pregnancy test ≥ 3 days later to document continued lack of a positive result.
* Male subjects who are sexually active, must agree, from Study Day 1 through at least 6 months after the last dose of study treatment, to practice protocol specified methods of contraception. Male subjects must agree to refrain from sperm donation from initial study treatment administration through at least 6 months after the last dose of study treatment.
* Subject must have a white blood cell count ≤ 25 × 10\^9/L. (Note: subjects who have undergone hydroxyurea administration or leukapheresis for therapeutic cytoreduction will be considered eligible).

Exclusion Criteria

* Subject has ECOG Performance Status \> 3, regardless of age.
* Subject has known Human Immunodeficiency Virus (HIV) infection (due to potential drug-drug interactions between antiretroviral medications and venetoclax). HIV testing will be performed at Pretreatment, if required per local guidelines or institutional standards.
* Subject has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Star fruit within 3 days prior to the initiation of study treatment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No